Analyst Report: AMGN

1. EXECUTIVE SUMMARY

On September 08, 2026, shares of Amgen Inc. (NASDAQ: AMGN) plummeted by -10.08% (losing $44.06 to close at $393.17), suffering its largest single-day percentage decline in over two decades. The primary catalyst behind the selloff was not a direct operational failure by Amgen, but a catastrophic read-across from competitor Novartis AG, whose Phase 3 trial for its investigational Lp(a)-lowering drug pelacarsen failed to reduce major adverse cardiovascular events (MACE). This unexpected result severely undermined market confidence in the entire lipoprotein(a) therapeutic class, placing Amgen’s high-conviction Phase 3 pipeline candidate, olpasiran, under significant clinical and commercial risk. The panic was further amplified by a valuation-driven downgrade from BMO Capital Markets to "Market Perform". Although Amgen released landmark positive Phase 3 survival data for its small cell lung cancer drug IMDELLTRA® on the same day, the market completely disregarded the positive readout. While the drop reflects a sharp derisking of Amgen’s cardiovascular pipeline, the reaction is a partial overreaction given Amgen’s broader commercial portfolio and its leading position in next-generation obesity therapeutics (MariTide).

2. THE CATALYST (CRITICAL)

Primary Trigger: Class-Wide Lp(a) Pipeline Shock

• What Happened: On Friday after market close (September 04, 2026, ahead of the U.S. Labor Day holiday weekend), Novartis AG and partner Ionis Pharmaceuticals disclosed top-line results from the pivotal Phase 3 Lp(a)HORIZON cardiovascular outcomes trial (8,323 patients). The study revealed that pelacarsen failed to meet its primary endpoint of reducing major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization) compared to placebo—despite successfully achieving substantial reductions in plasma lipoprotein(a) [Lp(a)] levels.
• Impact on Amgen: When markets opened on Tuesday, September 08, 2026 (the first trading session following the news), investors aggressively sold down Amgen due to read-across risk for olpasiran. Olpasiran is Amgen's investigational small interfering RNA (siRNA) therapy currently in the pivotal Phase 3 OCEAN(a)-Outcomes trial (7,297 patients with established atherosclerotic cardiovascular disease). Analysts and institutional investors had previously priced in a >65% probability of success for olpasiran; Novartis' failure raises fundamental questions about whether lowering Lp(a) biomarker concentrations yields actual clinical benefit (drawing parallels to historical CETP inhibitor trial failures).

Secondary Trigger: Wall Street Analyst Downgrade

• Analyst Action: On the morning of September 08, 2026, BMO Capital Markets analyst Evan David Seigerman downgraded Amgen (AMGN) from "Market Outperform" to "Market Perform".
• Rationale: BMO noted that after a ~34% to 44% YTD rally pushing AMGN near its 52-week high of $447.03, commercial execution and pipeline success were fully priced in as the base case. The analyst highlighted growing headwinds from pending loss-of-exclusivity (LOE) on legacy biologics and pricing pressures, concluding that the risk-reward ratio had become balanced.

Masked Positive News (Overshadowed Readouts)

• IMDELLTRA® (tarlatamab-dlle): On September 08, 2026, Amgen announced landmark Phase 3 DeLLphi-305 interim study results showing statistically significant and clinically meaningful improvements in Overall Survival (OS) and Progression-Free Survival (PFS) when combined with AstraZeneca's Imfinzi® in first-line extensive-stage small cell lung cancer (ES-SCLC).
• TEZSPIRE® (tezepelumab): Amgen and AstraZeneca also reported positive Phase 3 CROSSING study data in eosinophilic esophagitis.

Despite these dual late-stage oncology and immunology victories, market panic over the Lp(a) pipeline domino effect dominated price action.

3. COMPANY PROFILE

Core Business

Amgen Inc. is one of the world’s largest independent biotechnology pioneers. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics across oncology, hematology, cardiovascular disease, inflammatory conditions, rare diseases, and nephrology.

4. DEEP DIVE ANALYSIS

Fundamentals vs. Overreaction: Is the Selloff Justified?

The 10.08% selloff is partially an overreaction from a broad portfolio standpoint, but fully justified from a pipeline net present value (NPV) recalibration perspective:

1. Mechanistic & Potency Differences (Olpasiran vs. Pelacarsen):

   • Pelacarsen: An antisense oligonucleotide (ASO) that demonstrated 70%–80% Lp(a) reduction in Phase 2.
   • Olpasiran: A GalNAc-conjugated small interfering RNA (siRNA) achieving >95% Lp(a) reduction at higher doses.
   • Scientific Nuance: It remains possible that Lp(a) reduction must cross a higher potency threshold (>90%) over a longer sustained window to yield cardiovascular outcome benefits. However, financial markets treat class failures as systemic risks until proven otherwise.

2. The Loss-of-Exclusivity (LOE) Cliff:

   • Amgen faces impending patent expirations on legacy blockbusters like Prolia/Xgeva, Enbrel, and Otezla over the next 3–5 years, exposing ~$13 billion in annual revenues to biosimilar competition.
   • The market had heavily relied on two primary replacement growth pillars: Olpasiran (Cardiovascular) and MariTide (Obesity/GIP-GLP-1). Removing or discounting olpasiran’s expected $3B+ peak sales potential squeezes future revenue visibility.

3. MariTide Remains Intact:

   • Amgen’s cornerstone growth asset—MariTide (a monthly/bi-monthly GIP/GLP-1 receptor agonist in 9 Phase 3 clinical trials showing ~20% weight loss at 52 weeks without reaching a weight plateau)—remains unaffected by the Lp(a) outcome.

Bull Case vs. Bear Case

+-----------------------------------------------------------------------------------+
|                                 INVESTMENT THESIS                                 |
+--------------------------------------------------+--------------------------------+
| BULL CASE                                        | BEAR CASE                      |
+--------------------------------------------------+--------------------------------+
| 1. MariTide leadership in obesity market ($100B+ | 1. Olpasiran Phase 3 failure   |
|    TAM) offers massive multi-decade upside.      |    would erase $3B+ in NPV.   |
| 2. IMDELLTRA first-line ES-SCLC readout sets     | 2. Looming biosimilar erosion  |
|    new standard of care in oncology.             |    on Prolia/Xgeva & Enbrel.   |
| 3. Robust dividend yield (~2.5%) backed by       | 3. High debt-to-equity ratio   |
|    ~$8.6B annual free cash flow generation.      |    (~490%) post-Horizon deal.  |
+--------------------------------------------------+--------------------------------+

5. TECHNICAL SNAPSHOT

On September 08, 2026, AMGN closed at $393.17, trading in a session range of $391.17 to $415.90.

                                  AMGN TECHNICAL SNAPSHOT
  -----------------------------------------------------------------------------------
  Current Price: $393.17  |  20-Day SMA: $430.22  |  50-Day SMA: $397.75
  100-Day SMA:   $368.99  |  200-Day SMA: $358.69  |  RSI (14):   40.25 (Oversold Reset)
  -----------------------------------------------------------------------------------

• Volume Analysis: Trading volume exploded to 6.59 million – 6.83 million shares, roughly 3.2x the 30-day average daily volume (~2.08 million shares). Heavy institutional distribution is evident.
• Moving Average Breakouts: The stock sliced below its 20-day SMA ($430.22) and gapped below its 50-day SMA ($397.75). However, it held above its key 100-day SMA ($368.99) and long-term 200-day SMA ($358.69).
• Key Levels:
  • Immediate Support: $385.00 – $390.02 (August 2026 swing low).
  • Major Support: $365.00 – $368.99 (100-day SMA & fundamental GF Value floor).
  • Immediate Resistance: $397.75 – $405.00 (50-day SMA gap-down zone).
  • Major Resistance: $430.00 – $437.23 (Pre-drop consolidation level).

6. RISK FACTORS

1. Cardiovascular Pipeline Devaluation: If Amgen pauses, alters, or ultimately reports negative data for the Phase 3 OCEAN(a)-Outcomes trial, the company will forfeit a key future cardiovascular franchise.
2. Horizon Debt & Capital Allocation: Amgen maintains high debt levels following its $27.8B acquisition of Horizon Therapeutics (Debt/Equity ratio at ~490%). High debt service limits flexibility if pipeline failures occur.
3. Regulatory & Biosimilar Pressures: Key drugs face aggressive biosimilar competition, while European regulatory setbacks (such as EU/UK actions on Tavneos) present unexpected revenue drags.
4. Obesity Clinical Competition: MariTide Phase 3 trials face fierce competition from Eli Lilly (tirzepatide/retatrutide) and Novo Nordisk (cagrilintide/semaglutide). Any safety signal in MariTide would trigger severe equity devaluation.

7. ACTIONABLE OUTLOOK

Analyst Conclusion

Rating: HOLD / NEUTRAL. Amgen's drop on September 08, 2026, reflects a painful but necessary derisking of its Lp(a) asset. However, selling AMGN at 16.1x forward P/E ignores the commercial value of its oncology breakthroughs (IMDELLTRA) and its multi-billion dollar obesity candidate (MariTide). Institutional investors should wait for the stock to base near $380–$390 support before building or expanding long positions.